Exercise and Cardiac Stunning During HD

Sponsor
University of Manitoba (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04877041
Collaborator
Canadian Institutes of Health Research (CIHR) (Other)
160
2
31

Study Details

Study Description

Brief Summary

The purpose of this study is to determine the effect of a 12-week cycling during hemodialysis program on hemodialysis-induced myocardial stunning in adult individuals receiving hemodialysis.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Intradialytic Cycling
N/A

Detailed Description

People with kidney failure receiving chronic hemodialysis (HD) suffer from post-HD treatment fatigue, poor functional status and high rates of cardiac failure and death. Previous work has shown that these outcomes are correlated with recurrent ischemic cardiac injury (myocardial stunning) that occurs during HD treatments. Myocardial stunning, identified by regional cardiac wall motion abnormalities (RWMA), is common during HD. Intradialytic cycling (during HD) decreases HD-induced stunning, and may improve adverse outcomes associated with stunning. We will use echocardiography (echo) to understand the effects of intradialytic aerobic exercise on myocardial stunning and HD-related symptoms.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
160 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Masking Description:
Data analysts will also be blinded to study group
Primary Purpose:
Treatment
Official Title:
Trial of Intradialytic Cycling as Kidney Exercise Rehabilitation for Cardiac Stunning in Hemodialysis (TICKERS-HD)
Anticipated Study Start Date :
Aug 1, 2022
Anticipated Primary Completion Date :
Sep 1, 2024
Anticipated Study Completion Date :
Mar 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Exercise (Intradialytic Cycling)

Participants will receive a standardized baseline exercise counseling session as per control and then participate in a supervised intradialytic cycling program for 12-weeks

Behavioral: Intradialytic Cycling
This intervention will consist of intradialytic cycling for 60 minutes 3 times per week for a total of 12 weeks.

No Intervention: Usual Care

Participants will receive a standardized baseline exercise counseling session. Participants in the control group will not undergo formal exercise intervention, but will not be prohibited from participating in exercise outside of hemodialysis. They will be asked to not to participate in intradialytic cycling during the study (16 weeks total).

Outcome Measures

Primary Outcome Measures

  1. Change in number of cardiac RWMA at peak hemodialysis stress (last 30 min HD) from baseline to 12 weeks measured using echocardiography [Baseline to 12 weeks]

    Using standard left ventricular apical 2-, 3-, and 4-chamber views and left ventricular parasternal short-axis views collected by the same trained operator at each site 3 times during the mid-week hemodialysis session at each assessment time point as follows: baseline (pre hemodialysis), post-cycling exercise (or mid-dialysis in controls) and at peak hemodialysis stress (~30 min prior to end of hemodialysis). Echocardiogram image analysis will be performed in London, ON using automated speckle-tracking analysis (EchoPAC-PC software version 110.1.3; GE Healthcare).

Secondary Outcome Measures

  1. Change in post-hemodialysis high sensitivity Troponin T level from baseline to 12 weeks [Baseline to 12 weeks]

    Measured by Roche High-Sensitivity Troponin T assay at each site.

  2. Change in difference between pre-hemodialysis and post-hemodialysis Troponin T from baseline to 12 weeks [Baseline to 12 weeks]

    Measured by Roche High-Sensitivity Troponin T assay at each site.

  3. Change in severity of post-hemodialysis fatigue [Baseline to 12 weeks]

    Assessed by the self-reported answer (in minutes) to the question: "How long does it take you to recover from a dialysis session and resume your normal, usual activities?"

  4. Change in Symptom Burden [Baseline to 12 weeks]

    Measured using the Dialysis Symptom Index (DSI) Severity Score.

  5. Change in Exercise Capacity [Baseline to 12 weeks]

    Measured by the Incremental Shuttle Walk Test (ISWT)

  6. Change in Physical Activity Behaviour Patterns [Baseline to 12 weeks]

    Assessed using total active minutes per day as measure by multi-directional accelerometry

  7. Change in number of regional wall motion abnormalities at peak HD stress [Baseline to 1 week]

    Measured at each study time point to further assess how exercise training effects HD-related cardiac stunning over time

  8. Change in number of regional wall motion abnormalities at peak HD stress [Baseline to 14 weeks]

    Measured at each study time point to further assess how exercise training effects HD-related cardiac stunning over time

  9. Change in number of regional wall motion abnormalities at peak HD stress [Baseline to 16 weeks]

    Measured at each study time point to further assess how exercise training effects HD-related cardiac stunning over time

  10. Feasiblity - Recruitment [Baseline to 12 weeks]

    Proportion of individuals eligible for study that were recruited

  11. Feasibility - Eligibility [Baseline to 12 weeks]

    Proportion of individuals approached eligible for enrolment into study

  12. Feasibility - Adherence [Baseline to 16 weeks]

    Proportion of participants that completed the study

  13. Feasibility - Exercise Adherence [Baseline to 12 weeks]

    Proportion of total exercise sessions during study completed

  14. Feasibility - Exercise Adherence [Baseline to 12 weeks]

    Proportion of total possible minutes of intradialytic cycling completed during the study

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Adults > or equal to 18 years old (no upper age limit); who are > 3 months after starting maintenance hemodialysis

  • No expected change in dialysis modality, elective surgery or relocation outside of study site during the intervention period (16 weeks)

  • Assessed to be safe and able to exercise by the hemodialysis unit nephrologist

  • Able to communicate in English and provide written informed consent

Exclusion Criteria:
  • Acute coronary syndrome in the past 3 months

  • Unstable arrhythmia

  • Shortness of breath at rest or with minimal activity (NYHA Class 4)

  • Symptomatic hypoglycemia (>2x/week in week prior to enrolment)

  • Participating in clinical intradialytic cycling program in last 6 months (if a clinical program exists)

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • University of Manitoba
  • Canadian Institutes of Health Research (CIHR)

Investigators

  • Principal Investigator: Clara Bohm, MD, MPH, University of Manitoba

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of Manitoba
ClinicalTrials.gov Identifier:
NCT04877041
Other Study ID Numbers:
  • HS24857 (B2021:039)
First Posted:
May 7, 2021
Last Update Posted:
Jun 22, 2022
Last Verified:
Jun 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 22, 2022